PDF(Pubmed)
Abstract：
UNASSIGNED: Dysregulation of long noncoding RNAs (lncRNAs) has been reported to be associated with multiple tumors where they act as tumor suppressors or accelerators. The lncRNA CYTOR was identified as an oncogene involved in many cancers, such as gastric cancer, colorectal cancer, hepatocellular carcinoma, and renal cell carcinoma. However, the role of CYTOR in bladder cancer (BCa) has rarely been reported.
UNASSIGNED: Using cancer datasets from The Cancer Genome Atlas (TCGA) program, we analyzed the association between CYTOR expression and prognostic value, oncogenic pathways, antitumor immunity and immunotherapy response in BCa. The influence of CYTOR on the immune infiltration pattern in the urothelial carcinoma microenvironment was further verified in our dataset. Single-cell analysis revealed the role of CYTOR in the tumor microenvironment (TME) of BCa. Finally, we evaluated the expression of CYTOR in BCa in the Peking University First Hospital (PKU-BCa) dataset and its correlation with the malignant phenotype of BCa in vitro and in vivo.
UNASSIGNED: The results indicated that CYTOR was highly expressed in multiple cancer samples, including BCa, and increased CYTOR expression contributed to poor overall survival (OS). Additionally, elevated CYTOR expression was significantly correlated with clinicopathological features of BCa, such as female sex, advanced TNM stage, high histological grade and non-papillary subtype. Functional characterization revealed that CYTOR may be involved in immune-related pathways and the epithelial mesenchymal transformation (EMT) process. Moreover, CYTOR had a significant association with infiltrating immune cells, including M2 macrophages and regulatory T cells (Tregs). CYTOR facilitates the crosstalk between cancer-associated fibroblasts (CAFs) and macrophages, and mediates M2 polarization of macrophages. Correlation analysis revealed a positive correlation between CYTOR expression and programmed cell death-1 (PD-1)/programmed death ligand 1 (PD-L1)/expression and other targets for specific immunotherapy in BCa, which are recognized to predict the efficacy of immunotherapy.
UNASSIGNED: These results suggest that CYTOR serves as a potential biomarker for predicting survival outcome, TME cell infiltration characteristics and immunotherapy response in BCa.
UNASSIGNED: Using cancer datasets from The Cancer Genome Atlas (TCGA) program, we analyzed the association between CYTOR expression and prognostic value, oncogenic pathways, antitumor immunity and immunotherapy response in BCa. The influence of CYTOR on the immune infiltration pattern in the urothelial carcinoma microenvironment was further verified in our dataset. Single-cell analysis revealed the role of CYTOR in the tumor microenvironment (TME) of BCa. Finally, we evaluated the expression of CYTOR in BCa in the Peking University First Hospital (PKU-BCa) dataset and its correlation with the malignant phenotype of BCa in vitro and in vivo.
UNASSIGNED: The results indicated that CYTOR was highly expressed in multiple cancer samples, including BCa, and increased CYTOR expression contributed to poor overall survival (OS). Additionally, elevated CYTOR expression was significantly correlated with clinicopathological features of BCa, such as female sex, advanced TNM stage, high histological grade and non-papillary subtype. Functional characterization revealed that CYTOR may be involved in immune-related pathways and the epithelial mesenchymal transformation (EMT) process. Moreover, CYTOR had a significant association with infiltrating immune cells, including M2 macrophages and regulatory T cells (Tregs). CYTOR facilitates the crosstalk between cancer-associated fibroblasts (CAFs) and macrophages, and mediates M2 polarization of macrophages. Correlation analysis revealed a positive correlation between CYTOR expression and programmed cell death-1 (PD-1)/programmed death ligand 1 (PD-L1)/expression and other targets for specific immunotherapy in BCa, which are recognized to predict the efficacy of immunotherapy.
UNASSIGNED: These results suggest that CYTOR serves as a potential biomarker for predicting survival outcome, TME cell infiltration characteristics and immunotherapy response in BCa.
摘要：
未经证实：据报道，长链非编码RNA（lncRNAs）的失调与多种肿瘤相关，它们作为肿瘤抑制因子或加速器。lncRNACYTOR被鉴定为与许多癌症有关的癌基因，比如胃癌，结直肠癌,肝细胞癌，和肾细胞癌。然而,CYTOR在膀胱癌(BCa)中的作用鲜有报道.
未经评估：使用癌症基因组图谱（TCGA）程序中的癌症数据集，我们分析了CYTOR表达与预后价值之间的关系，致癌途径，BCa的抗肿瘤免疫和免疫治疗反应。在我们的数据集中进一步验证了CYTOR对尿路上皮癌微环境中免疫浸润模式的影响。单细胞分析揭示了CYTOR在BCa的肿瘤微环境（TME）中的作用。最后,我们在北京大学第一医院（PKU-BCa）数据集中评估了CYTOR在BCa中的表达及其与BCa恶性表型的相关性。
未经证实：结果表明CYTOR在多个癌症样本中高表达，包括BCa,CYTOR表达增加导致总生存期（OS）较差。此外,CYTOR表达升高与BCa的临床病理特征显着相关，比如女性，高级TNM阶段，高组织学分级和非乳头状亚型。功能表征显示CYTOR可能参与免疫相关途径和上皮间质转化（EMT）过程。此外，CYTOR与浸润免疫细胞有显著关联,包括M2巨噬细胞和调节性T细胞(Tregs)。CYTOR促进癌症相关成纤维细胞（CAF）和巨噬细胞之间的串扰，并介导巨噬细胞的M2极化。相关分析显示CYTOR表达与程序性细胞死亡-1(PD-1)/程序性死亡配体1(PD-L1)/表达与BCa其他特异性免疫治疗靶点呈正相关,这是公认的预测免疫疗法的疗效。
未经证实：这些结果表明CYTOR是预测生存结果的潜在生物标志物，BCa中TME细胞浸润特征和免疫治疗反应。
未经评估：使用癌症基因组图谱（TCGA）程序中的癌症数据集，我们分析了CYTOR表达与预后价值之间的关系，致癌途径，BCa的抗肿瘤免疫和免疫治疗反应。在我们的数据集中进一步验证了CYTOR对尿路上皮癌微环境中免疫浸润模式的影响。单细胞分析揭示了CYTOR在BCa的肿瘤微环境（TME）中的作用。最后,我们在北京大学第一医院（PKU-BCa）数据集中评估了CYTOR在BCa中的表达及其与BCa恶性表型的相关性。
未经证实：结果表明CYTOR在多个癌症样本中高表达，包括BCa,CYTOR表达增加导致总生存期（OS）较差。此外,CYTOR表达升高与BCa的临床病理特征显着相关，比如女性，高级TNM阶段，高组织学分级和非乳头状亚型。功能表征显示CYTOR可能参与免疫相关途径和上皮间质转化（EMT）过程。此外，CYTOR与浸润免疫细胞有显著关联,包括M2巨噬细胞和调节性T细胞(Tregs)。CYTOR促进癌症相关成纤维细胞（CAF）和巨噬细胞之间的串扰，并介导巨噬细胞的M2极化。相关分析显示CYTOR表达与程序性细胞死亡-1(PD-1)/程序性死亡配体1(PD-L1)/表达与BCa其他特异性免疫治疗靶点呈正相关,这是公认的预测免疫疗法的疗效。
未经证实：这些结果表明CYTOR是预测生存结果的潜在生物标志物，BCa中TME细胞浸润特征和免疫治疗反应。
